Last $0.97 USD
Change Today +0.0598 / 6.57%
Volume 19.4K
VSCI On Other Exchanges
As of 8:10 PM 10/24/14 All times are local (Market data is delayed by at least 15 minutes).

vision-sciences inc (VSCI) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/7/14 - $1.75
52 Week Low
11/1/13 - $0.78
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for VISION-SCIENCES INC (VSCI)

Related News

No related news articles were found.

vision-sciences inc (VSCI) Related Businessweek News

No Related Businessweek News Found

vision-sciences inc (VSCI) Details

Vision-Sciences, Inc., through its subsidiaries, designs, develops, manufactures, and markets endoscopy products. It operates through Medical and Industrial segments. The Medical segment designs, manufactures, and sells endoscopy-based products, including flexible fiber and video endoscopes; and EndoSheath disposables. This segment offers cystoscopes to urologists; bronchoscope to intensivists, pulmonologists, thoracic surgeons, and other airway-related physicians; trans-nasal esophagoscopy to general surgeons, primarily bariatric and gastroesophageal reflux disease surgeons, and gastroenterology physicians, as well as ear, nose, and throat (ENT) physicians and others; and ENT endoscopes to ENT physicians and speech pathologists. The Industrial segment designs, manufactures, and sells borescopes products, such as modulars, slim levers, knobs, battery operated portable flexible borescopes, industrial videoscopes, and portable video processors primarily to the aircraft engine manufacturing and aircraft engine maintenance industries. The company distributes its products through direct sales representatives in the United States; and through independent distributors in Europe, Asia, Australia, Canada, the Middle East, Africa, and central and South America. The company was founded in 1987 and is headquartered in Orangeburg, New York.

105 Employees
Last Reported Date: 05/30/14
Founded in 1987

vision-sciences inc (VSCI) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $210.9K
Vice President of Disposables Operations
Total Annual Compensation: $170.0K
Vice President of Machida
Total Annual Compensation: $155.0K
Compensation as of Fiscal Year 2014.

vision-sciences inc (VSCI) Key Developments

Vision-Sciences Announces CE Mark and European Launch of Next Generation EndoSheath(R) Bronchoscopy System

Vision-Sciences Inc. announced the CE Mark approval and European launch of the company's next generation video bronchoscope and EndoSheath(R) technology. The new BRS-5100 video bronchoscope was introduced at the annual ERS (European Respiratory Society) Meeting in Munich, Germany on September 7-10, 2014. Vision-Sciences' new EndoSheath(R) bronchoscopy system is the latest addition to its innovative endoscopy line for the Critical Care/Pulmonology market. The BRS-5100 digital video bronchoscope features design improvements for instrument maneuverability, suction capacity, and handling ergonomics intended to enhance the physician ease-of-use while providing the unparalleled efficiency, cost-efficacy, and patient safety of the sterile, disposable EndoSheath(R) technology. The BRS-5100 bronchoscope is compatible with the company's proprietary Vision System(R) platform, including the 7000 Series, the new all-in-one ultra-portable endoscopy imaging system. The Vision System provides high resolution CCD-based imaging with full screen presentation and an enhanced user interface with work-flow efficiency tools. Additionally, the platform includes plug-and-play simplicity for video, still, and audio documentation, including frame-by-frame review or historical image comparison ideal for patient progress review. EndoSheath(R) Bronchoscopy and Vision System(R) Key Features: An 'always ready, always sterile' flexible bronchoscopy solution for Critical Care and Pulmonology; Unparalleled imaging system portability, providing availability in almost any setting; EndoSheath models with different operative channel sizes, uniquely allowing the physician to "customize" the bronchoscope to fit the procedure; Simplified, rapid cleaning routine focused on patient safety and staff productivity; Reduced hospital spending on capital equipment and equipment service.

Vision-Sciences Inc. Introduces Flexible Video Laryngoscope to Ear-Nose-and Throat Market

Vision-Sciences Inc. announced the introduction of the company's next generation video laryngoscope. The company unveiled the new ENT-7000 model at the annual AAO-HNS Meeting (American Academy of Otolaryngology -- Head and Neck Surgery) held in Orlando, Florida on September 21-24, 2014. Vision-Sciences new video flexible laryngoscopy system is the company's first branded addition to its innovative 7000 Series endoscopy line. The advanced CCD-based laryngoscope features the smallest diameter insertion tube available. At 2.4mm in size, it provides clinicians with high performance imaging and maximizes patient comfort during diagnostic procedures. ENT-7000 is fully compatible with the 7000 Series Vision System(R), the company's next generation all-in-one ultra-portable endoscopy imaging platform. The Vision System platform provides high-resolution visualization and an enhanced user interface with work-flow efficiency tools. The platform also includes plug-and-play simplicity for video, still, and audio documentation, including frame-by-frame review or historical image comparison ideal for patient progress review. ENT-7000 Flexible Video Laryngoscope and Vision System(R) key features includes 2.4mm Insertion Tube for optimal patient comfort and passage in small anatomical spaces, high resolution CCD-based imaging for vivid, crisp visualization of anatomy, Full Vision System(R) compatibility - including stroboscopy, audio/video recording, frame-by-frame diagnostic review, and patient record management capabilities and compatible for use with the sterile, disposable EndoSheath(R) Technology.

Vision-Sciences Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended June 30, 2014

Vision-Sciences Inc. reported unaudited consolidated earnings results for the first quarter ended June 30, 2014. For the quarter, the company reported net sales of USD 3,752,000 against USD 3,652,000 a year ago. Operating loss was USD 1,878,000 against USD 2,389,000 a year ago. Loss before provision for income taxes was USD 1,977,000 against USD 2,434,000 a year ago. Net loss was USD 1,977,000 against USD 2,434,000 a year ago. Net loss per common share - basic and diluted was USD 0.04 against USD 0.05 a year ago. Net cash used in operating activities was USD 945,000 against USD 1,419,000 a year ago. Purchases of property and equipment were USD 25,000. Net sales were increased by 3% compared the same period a year ago, attributable to higher sales in the critical care/pulmonology market of its endoscopes and EndoSheath technology.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VSCI:US $0.97 USD +0.0598

VSCI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bacterin International Holdings Inc $4.11 USD -0.16
Cardica Inc $1.00 USD -0.05
Cytori Therapeutics Inc $0.51 USD -0.0189
Stereotaxis Inc $1.98 USD -0.02
Uroplasty Inc $2.45 USD -0.04
View Industry Companies

Industry Analysis


Industry Average

Valuation VSCI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.4x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VISION-SCIENCES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at